lenalidomide

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor

Related drugs:

No biomarker	Marginal Zone Lymphoma	No biomarker	Marginal Zone Lymphoma	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1	rituximab + lenalidomide Sensitive: A1 - Approval rituximab + lenalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval lenalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1	lenalidomide + daratumumab and hyaluronidase-fihj Sensitive: A1 - Approval lenalidomide + daratumumab and hyaluronidase-fihj Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + elotuzumab Sensitive: A1 - Approval lenalidomide + elotuzumab Sensitive : A1	lenalidomide + elotuzumab Sensitive: A1 - Approval lenalidomide + elotuzumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + daratumumab Sensitive: A1 - Approval lenalidomide + daratumumab Sensitive : A1	lenalidomide + daratumumab Sensitive: A1 - Approval lenalidomide + daratumumab Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + ixazomib Sensitive: A1 - Approval lenalidomide + ixazomib Sensitive : A1	lenalidomide + ixazomib Sensitive: A1 - Approval lenalidomide + ixazomib Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lenalidomide + tafasitamab-cxix Sensitive: A1 - Approval lenalidomide + tafasitamab-cxix Sensitive : A1	lenalidomide + tafasitamab-cxix Sensitive: A1 - Approval lenalidomide + tafasitamab-cxix Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + carfilzomib Sensitive: A1 - Approval lenalidomide + carfilzomib Sensitive : A1	lenalidomide + carfilzomib Sensitive: A1 - Approval lenalidomide + carfilzomib Sensitive : A1
Chr del(5q)	Myelodysplastic Syndrome	Chr del(5q)	Myelodysplastic Syndrome	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1	lenalidomide Sensitive: A1 - Approval lenalidomide Sensitive : A1
No biomarker	Multiple Myeloma	No biomarker	Multiple Myeloma	lenalidomide + bortezomib Sensitive: A2 - Guideline lenalidomide + bortezomib Sensitive : A2	lenalidomide + bortezomib Sensitive: A2 - Guideline lenalidomide + bortezomib Sensitive : A2
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2
No biomarker	Peripheral T-cell Lymphoma	No biomarker	Peripheral T-cell Lymphoma	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2
No biomarker	Diffuse Large B Cell Lymphoma	No biomarker	Diffuse Large B Cell Lymphoma	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
No biomarker	Mantle Cell Lymphoma	No biomarker	Mantle Cell Lymphoma	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
No biomarker	Follicular Lymphoma	No biomarker	Follicular Lymphoma	lenalidomide + obinutuzumab Sensitive: A2 - Guideline lenalidomide + obinutuzumab Sensitive : A2	lenalidomide + obinutuzumab Sensitive: A2 - Guideline lenalidomide + obinutuzumab Sensitive : A2
No biomarker	Hodgkin Lymphoma	No biomarker	Hodgkin Lymphoma	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
TP53 mutation	Small Lymphocytic Lymphoma	TP53 mutation	Small Lymphocytic Lymphoma	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
Chr del(17p)	Small Lymphocytic Lymphoma	Chr del(17p)	Small Lymphocytic Lymphoma	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2	rituximab + lenalidomide Sensitive: A2 - Guideline rituximab + lenalidomide Sensitive : A2
CALR mutation	Myelodysplastic Syndrome	CALR mutation	Myelodysplastic Syndrome	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2	lenalidomide Sensitive: A2 - Guideline lenalidomide Sensitive : A2

lenalidomide

Associations
(127)

Associations
(127)

lenalidomide

Associations(127)

Associations(127)

Associations
(127)

Associations
(127)